What's Happening?
Researchers at University College London (UCL) have developed a new hydrogel-based axon model to improve the testing of remyelination therapies for multiple sclerosis (MS). This model, described in a paper published in Nature Methods, aims to replicate
the physical properties of human axons more accurately than previous rigid models. The hydrogel-based model uses micropillars made from polyacrylamide, which can be adjusted to match the softness of real axons. This innovation addresses a significant challenge in MS research, where many drug candidates fail in human trials despite showing promise in traditional lab models. The UCL team, led by Professor Emad Moeendarbary, believes that this more realistic model can provide a better platform for early drug testing and the discovery of new therapies.
Why It's Important?
The development of a more accurate model for testing MS therapies is crucial as it could lead to more effective treatments reaching clinical trials. Current models often fail to replicate the physical environment of the human brain, leading to misleading results. By providing a more realistic testing ground, the UCL model could reduce the number of ineffective drugs progressing to costly human trials. This advancement has the potential to accelerate the development of therapies that can repair myelin, the protective sheath around axons that is damaged in MS. Successful therapies could significantly improve the quality of life for individuals with MS and other neurodegenerative diseases.
What's Next?
The UCL team plans to use their hydrogel-based model to test various remyelination drug candidates. The model's design allows for high-content imaging and systematic variation of mechanical cues, which could help researchers understand the myelination process better. If successful, this model could become a standard tool in MS research, potentially leading to breakthroughs in treatment options. The research community will likely monitor the outcomes of these tests closely, as they could inform future drug development strategies.
